Merrimack Pharmaceuticals Inc (MACK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 234,160 | 5,989 | 6,083 | 10,131 | 19,401 |
| Marketable Securities | 9,950 | 12,886 | 12,821 | 8,837 | N/A |
| TOTAL | $244,319 | $19,184 | $19,294 | $19,442 | $19,628 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 3 | 4 | 5 | 6 | 7 |
| TOTAL | $3 | $4 | $5 | $6 | $7 |
| Total Assets | $244,322 | $19,188 | $19,299 | $19,448 | $19,635 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 566 | 441 | 493 | 411 | 463 |
| TOTAL | $22,672 | $441 | $493 | $411 | $463 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $22,672 | $441 | $493 | $411 | $463 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 14,788 | 14,516 | 14,321 | 14,321 | 14,260 |
| Common Shares | 1,345 | 1,343 | 1,343 | 1,343 | 1,343 |
| Retained earnings | -347,447 | -548,817 | -548,577 | -548,298 | -547,907 |
| TOTAL | $221,650 | $18,747 | $18,806 | $19,037 | $19,172 |
| Total Liabilities And Equity | $244,322 | $19,188 | $19,299 | $19,448 | $19,635 |